Professor Anthony Howell 

2012

• Is cancer in a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism.Ertel A, Tsirigos A, Whitaker-Menezes D, Birbe RC, Pavlides S, Martinez-Outschoorn UE, Pestell RG, Howell A, Sotgia F, Lisanti MP.Cell Cycle. 2012 Jan 15;11(2). eScholarID:149407

2011

• D Gareth Evans & Anthony Howell. (2011). An Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers. Journal of Clinical Oncology in press, eScholarID:137314
• Accelerated aging in the tumor microenvironment: Connecting aging, inflammation and cancer metabolism with personalized medicine. Lisanti MP, Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, Sotgia F. Cell Cycle. 2011 Jul 1;10(13):2059-63. eScholarID:149068
• Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP.Cancer Biol Ther. 2011 Nov 15;12(10). eScholarID:149084
• Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role Of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment.Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti MP, Sotgia F.Cell Cycle. 2010 Sep 1;9(17):3515-33. eScholarID:149077
• Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment.Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti MP, Sotgia F.Cell Cycle. 2010 Sep 1;9(17):3515-33. eScholarID:149090
• Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: Implications for PET imaging of human tumors. Martinez-Outschoorn UE, Lin Z, Trimmer C, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. Cell Cycle. 2011 Aug 1;10(15). eScholarID:149070
• Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors.Martinez-Outschoorn UE, Lin Z, Trimmer C, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. Cell Cycle. 2011 Aug 1;10(15):2504-20. eScholarID:149074
• Caveolin-1 (P132L) Somatic Mutation in Human Breast Cancer. Newman W, Ferraldeschi R, Latif A, Clarke R, Spence K, O’Sullivan J, Howell A. Cancer Epidemiology, Biomarkers & Prevention. In press. eScholarID:149093
• Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Annu Rev Pathol. 2011 Oct 25. [Epub ahead of print]. eScholarID:149092
• Caveolin-1 and Mitochondrial SOD2 (MnSOD) Function as Tumor Suppressors in the Stromal Microenvironment: A New Genetically Tractable Model for Human Cancer Associated Fibroblasts. Casey Trimmer, Federica Sotgia1, Diana Whitaker-Menezes, Renee M. Balliet,Gregory Eaton, Ubaldo E. Martinez-Outschoorn1, Stephanos Pavlides, Anthony, Howell, Renato V. Iozzo, Richard G. Pestell, Philipp E. Scherer, Franco, Capozza, and Michael P. Lisanti. Cell Cycle 2011 Dec 1;10(23):4047-64. eScholarID:149096
• Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Trimmer C, Sotgia F, Whitaker-Menezes D, Balliet RM, Eaton G, Martinez-Outschoorn UE, Pavlides S, Howell A, Iozzo RV, Pestell RG, Scherer PE, Capozza F, Lisanti MP. Cancer Biol Ther. 2011 Feb 15;11(4):383-94. eScholarID:149051
• Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG. Breast Cancer Res Treat. 2011 Jan;125(1):279-87. eScholarID:149050
• Cytokine production and inflammation drive autophagy in the tumor microenvironment: Role of stromal caveolin-1 as a key regulator.Martinez-Outschoorn UE, Whitaker-Menezes D, Lin Z, Flomenberg N, Howell A, Pestell RG, Sotgia F, Lisanti MP, Sotgia F. Cell Cycle. 2011 Jun 1;10(11):5918-201. eScholarID:149060
• Defining bad stroma in human breast tumors. Howell A. Cell Cycle. 2011 Sep 15;10(18):3056. eScholarID:149078
• Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R.Lancet. 2011 Nov 12;378(9804):1707-16. eScholarID:149082
• Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review.Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, Narod SA. Cancer Treat Rev. 2011 Jul 18. eScholarID:149086
• Energy transfer in "parasitic" cancer metabolism: Mitochondria are the powerhouse and Achilles' heel of tumor cells. Martinez-Outschoorn UE, Pestell RG, Howell A, Nagajyothi F, Machado FS, Tanowitz HB, Sotgia F, Lisanti MP. Cell Cycle. 2011 Dec 15;10(24). eScholarID:149085
• Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, Birbe RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philp NJ, Lisanti MP.Cell Cycle. 2011 Jun 1;10(11):1772-83. eScholarID:149062
• From prediction to prevention via screening. Howell A Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant J, Newman W, Buchan I, Cuzick J,. Evans DG. Journal of Internal Medicine in press. eScholarID:149095
• Fulvestrant re-visited: efficacy and safety of the 500mg dose. Howell A, Sapunar FClinical Breast Cancer 2011 Aug;11(4):204-2010. eScholarID:149069
• Fulvestrant revisited: efficacy and safety of the 500-mg dose.Howell A, Sapunar F. Clin Breast Cancer. 2011 Aug;11(4):204-10. eScholarID:149075
• Hormone replacement therapy and breast cancer. Howell A, Evans GD. Recent Results Cancer Res.Jan 2011;188:115-24. eScholarID:149048
• Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: The seed and soil also needs "fertilizer". Lisanti MP, Martinez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, Sotgia F.Cell Cycle. 2011 Aug 1;10(15). eScholarID:149073
• Hyperactivation of Oxidative Mitochondrial Metabolism in Epithelial Cancer Cells In Situ: Visualizing the Therapeutic Effects of Metformin in Tumor TissueDiana Whitaker-Menezes , Ubaldo E. Martinez-Outschoorn Neal Flomenberg , Ruth C. Birbe Agnieszka K. Witkiewicz , Anthony Howell Stephanos Pavlides , Richard G. Pestell , Carlo Minetti , Paolo Broda , Michael P. Lisanti and Federica Sotgia in press. eScholarID:149097
• Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trial. Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J. J Clin Oncol. 2011 Nov 10;29(32):4266-72. eScholarID:149080
• Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: Achieving personalized medicine via Metabolo-Genomics. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C, Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F, Lisanti MP. Cell Cycle. 2011 Apr 15;10(8):1271-86. eScholarID:149054
• Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW, Coleman RE. Ann Oncol. 2011 Apr;22(4):857-62. eScholarID:149055
• Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Castello-Cros R, Bonnuccelli G, Molchansky A, Capozza F, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, Whitaker-Menezes D, Sotgia F, Lisanti MP. Cell Cycle. 2011 Jun 15;10(12):2021-34. eScholarID:149064
• Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: Significant bone health issues in those not taking HRT. Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, Selby P, Howell A, Evans DG. British Journal of Cancer Jun 28;105(1):22-7. eScholarID:149065
• Predictive algorithms for adjuvant therapy: TransATAC. Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Found ER, Forbes J, Pineda S, Cuzick J.Steroids. 2011 Jul;76(8):777-80. eScholarID:149067
• Prevelance of of testing for BRCA1 and BRCA2 mutations in triple negative breast cancer. Evans DG, Howell A, Lalloo F, Eccles DM. J Med Genet 2011 Aug; 48(8):520-2. eScholarID:149071
• Preventive therapy for breast cancer: a consensus statement. Cuzick J, Decensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Lancet Oncol. 2011 May;12(5):496-503. eScholarID:149058
• Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer.Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF. J Clin Oncol. 2011 Nov 10;29(32):4273-8. eScholarID:149081
• Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth.Chiavarina B, Whitaker-Menezes D, Martinez-Outschoorn UE, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, Smith J, Daniel R, Sotgia F, Lisanti MP.Cancer Biol Ther. 2011 Dec 15;12(12). eScholarID:149406
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Lancet. 2011 Aug 27;378(9793):771-84. eScholarID:149076
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG) Lancet July 29th 2011. eScholarID:149087
• Stromal-epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB, Sotgia F, Lisanti MP. Int J Biochem Cell Biol. 2011 Jul; 43(7): 1045-51. eScholarID:149066
• Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. Maurice A, Evans DG, Affen J, Greenhalgh R, Duffy SW, Howell A. Int J Cancer. 2011 Aug 23. doi: 10.1002/ijc.26394. eScholarID:149088
• Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM. J Natl Cancer Inst. 2011 May 4;103(9):744-52. eScholarID:149056
• The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women.Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A, Howell A. Int J Obes (Lond). 2011 May;35(5):714-27. eScholarID:149059
• Understanding the metabolic basis of drug resistance: Therapeutic induction of the Warburg effect kills cancer cells. Martinez-Outschoorn UE, Lin Z, Ko YH, Goldberg AF, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. Cell Cycle. 2011 Aug 1;10(15). eScholarID:149072
• Warburg Meets Autophagy: Cancer Associated Fibroblasts AccelerateTumor Growth and Metastasis Via Oxidative Stress, Mitophagy andAerobic Glycolysis. Stephanos Pavlides, Iset Vera , Ricardo Gandara, Sharon Sneddon , Richard G.Pestell , Isabelle Mercier , Ubaldo E. Martinez-Outschoorn , Diana Whitaker-Menezes, Anthony Howell, Federica Sotgia, and Michael P. Lisanti Antioxidant and Redox Signalling Sep [Epub ahead of print]. eScholarID:149089

2010

• Adherence to a diet and exercise weight loss intervention amongst women at increased risk of breast cancer. Harvie M, Cohen H, Mason C, Mercer T, Malik R, Adams J, Evans DGR, Hopwood P, Cuzick J, Howell A. The Open Obesity Journal 2: 71-80, 2010. eScholarID:149015
• Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal icroenvironment.Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti MP, Sotgia F. Cell Cycle. 2010 Sep;9(17):3515-3. eScholarID:149032
• Breast cancer susceptibility variants alter risk in familial ovarian cancer. Latif A, McBurney HJ, Roberts SA, Lalloo F, Howell A, Evans DG, Newman WG. Fam Cancer. 2010 Dec;9(4):503-6. eScholarID:149047
• Breast cancer susceptibility variants alter risks in familial cancer.Latif A, Hadfield KD, Roberts SA, Shenton A, Lalloo F, Black GCM, Howell A, Evans DG, Newman WG. J Med Genet 47 (2): 126-31, 2010. eScholarID:149013
• Breast tumour stroma is a prognostic indicator and target for therapyHowell A, Landberg G and Bergh B. Breast Cancer Research 11, supplement 3: S16, 2009. eScholarID:149016
• Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer? Howell A. BMC Med. 2010 Nov 16;8:73. eScholarID:149039
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators. Lancet Oncol. 2010 Dec;11(12):1135-41. eScholarID:149044
• Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. J Clin Oncol 20; 28(21): 3411-5, 2010. eScholarID:149025
• Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. J Clin Oncol. 2010 Jul 20;28(21):3411-5. eScholarID:149029
• Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Flomenberg N, Tsirigos A, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Cell Cycle 9 (12), 2010. eScholarID:149026
• Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Flomenberg N, Tsirigos A, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Cell Cycle. 2010 Jun 6;9(12): 2412-22. eScholarID:149028
• HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE,Pavlides S, Howell A, Tanowitz HB, Casimiro MC, Wang C, Pestell RG, Grieshaber P, Caro J, Sotgia F, Lisanti MP. Cell Cycle. 2010 Sep;9(17):3534-51. eScholarID:149036
• Increase in serum total IGF-I and maintenance of free IGF-I following intentional weight loss in pre-menopausal women at increased risk of breast cancer.Harvie M, Renehan AG, Frystyk J, Flyvbjerg A, Mercer T, Malik R, Adams J, Cuzick J, Howell A. The Open Obesity Journal 2: 63-70, 2010. eScholarID:149014
• Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer. Howell A, Bergh J. J Clin Oncol. 2010 Oct 20;28(30):4548-50. eScholarID:149037
• Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, lomenberg N, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Cell Cycle. 2010 Sep;9(17):3506-14. eScholarID:149031
• Long term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Evans DG, Moran A, Hartley R, Dawson J, Bulman B, Knox F, Howell A, Lalloo F. Br J Cancer 102 (7): 1091-8, 2010. eScholarID:149022
• Lung cancer after treatment for breast cancer. Lorigan P, Califano R, Faivre-Finn C, Howell A, Thatcher N. Lancet Oncol. 2010 Dec;11(12):1184-92. eScholarID:149046
• Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. FH01 collaborative teams. Lancet Oncol. 2010 Dec;11(12):1127-34. eScholarID:149043
• Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, Lisanti MP. Cell Cycle. 2010 Aug 15;9(16):3256-76. eScholarID:149030
• Prediction of risk of distant recurrence using the 21 gene recurrence score in node negative and node positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen. A TransATAC study. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarinit R, Baehner FL, Shak S. J Clin Oncol, 28(11):1829-34, 2010. eScholarID:149023
• RASSF1A polymorphism in familial breast cancer. Bergqvist J, Latif A, Roberts SA, Hadfield KD, Lalloo F, Howell A, Evans DG, Newman WG. Fam Cancer. 2010 Sep;9(3):263-5. eScholarID:149034
• Significant differences in UK and US female bone density reference ranges. Noon E, Singh S, Cuzick J, Spector TD, Williams FM, Frost ML, Howell A, Harvie M, Eastell R, Coleman RE, Fogelman I, Blake GM; IBIS-II Bone Substudy. Osteoporos Int. 2010 Nov;21(11):1871-80. eScholarID:149040
• Significant Differences in UK and US Female Bone Density Reference Ranges. Noon E, Singh S, Cuzick J, Spector TD, Williams FMK, Frost ML, Howell A, Harvie M, Eastell R, Coleman RE, FogelmanI, Blake GM for the IBIS-II Bone Sub-Study. Osteoporosis Int, epub ahead of print, 2010. eScholarID:149024
• The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Casey T, Tsirigos A, Migneco G, Witkiewicz A, Balliet R, Mercier I, Wang C, Flomenberg N, Howell A, Lin Z, Caro J, Pestell RG, Sotgia F, Lisanti MP. Cell Cycle. 2010 Nov;9(21):4297-306. eScholarID:149038
• The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG, Martinez- Outschoorn UE, Howell A, Sotgia F, Lisanti MP.Cell Cycle. 2010 Sep;9(17):3485-505. eScholarID:149035
• The emerging breast cancer epidemic: early diagnosis and treatment. Howell A.Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S10. eScholarID:149042
• The globalisation of breast cancer. Boyle P, Howell A. Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S7. eScholarID:149041
• Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, Migneco G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg N, Howell A, Pestell RG, Lisanti MP, Sotgia F. Cell Cycle. 2010 Jun 12;9(12): 2423-33. eScholarID:149027
• Undersirable gynaecololgical and operative interventions during treatment of breast cancer with anastrozole and tamoxifen. Distler W, Canzler U, Duffy SR, Howell A, Cuzick J, Baum M. Geburtsh Frauenheilk 70: 57-61, 2010. eScholarID:149021
• Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-evironment.Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A, Witkiewicz A, Lin Z, Balliet R, Howell A, Sotgia F. Cancer Biol Ther. 2010 Sep;10(6):537-42. eScholarID:149033
• Uptake of breast cancer prevention and screening trials. Evans DG, Harvie M, Bundred N, Howell A. J Med Genet. 2010 Dec;47(12):853-5. eScholarID:149045

2009

• Blance RR, Sims A, Anderson E, Howell A-, Clarke RB. (2009). Normal breast tissue implanted into athymic nude mice identifies biomarkers of the effects of human pregnancy levels of estrogen. Cancer Prev Res (Phila Pa), 2(3), 257-264. eScholarID:1d32439 | DOI:10.1158/1940-6207.CAPR-08-0161
• Biomarkers of dietary energy restriction in women at increased risk of breast cancer. Ong KR, Sims AH, Harvie M, Chapman M, Dunn WB, Broadhurst D, Goodacre R, Wilson M, Thomas N, Clarke RB, Howell A.Cancer Prev Res 2 (8): 2318-24, 2009. eScholarID:149012
• Controversies in Breast Cancer, Edinburgh, 7–8 September 2009.Introduction to Session 1 Howell A, Cuzick J. Breast Cancer Research 11, supplement 3: S2, 2009. eScholarID:149018
• Controversies in hormonal adjuvant therapy for premenopausal patients.Howell A. Breast Cancer Res. 2009 Jun 23;11 Suppl 1:S14. eScholarID:149019
• Risk factors. Introduction to Session 1. Howell A, Cuzick J. Breast Cancer Res 11 supp 3: S2, 2009. eScholarID:149017

2007

• Lavelle KJ, Todd C, Moran A, Howell A-, Bundred NJ, Campbell MG. (2007). Non-standard management of breast cancer increases with age in the UK: a population based cohort of women >65 years. British Journal Of Cancer, 96(8), 1197-1203. eScholarID:1d27639 | DOI:10.1038/sj.bjc.6603709
• Malinovszky, K, Johnston, S, Barrett-Lee, P, Howell, A-, Verrill, M, O'reilly, S, Houston, S, Wardley, A, Grieve, R, Leonard, R. (2007). TEXAS (Taxotere(R) EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC. Cancer Chemother Pharmacol, 59( 3), 413-8. eScholarID:1d31004

2006

• Bramley M, Clarke RB, Howell A-, Evans DDGR, Armer T, Baildam AD, Anderson E. (2006). Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. Br J Cancer, 94( 7), 1021-8. eScholarID:1d12966 | DOI:10.1038/sj.bjc.6603042
• Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A-. (2006). Quality of Life of Postmenopausal Women in the ATAC ("Arimidex", Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer. Breast Cancer Res Treat, 100( 3), 273-84. eScholarID:1d30998
• Cuzick J, Sasieni P, Howell A-. (2006). Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer, 94( 4), 460-4. eScholarID:1d31000
• Harvie M, Howell A-. (2006). Energy balance adiposity and breast cancer - energy restriction strategies for breast cancer prevention. Obes Rev, 7( 1), 33-47. eScholarID:1d30997
• Howell A-. (2006). Fulvestrant ('Faslodex'): current and future role in breast cancer management. Crit Rev Oncol Hematol, 57( 3), 265-73. eScholarID:1d31035
• Howell A-. (2006). Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator? Int J Gynecol Cancer, 16 Suppl 2, 521-3. eScholarID:1d31573
• Lalloo, F, Varley, J, Moran, A, Ellis, D, O'dair, L, Pharoah, P, Antoniou, A, Hartley, R, Shenton, A, Seal, S, Bulman, B, Howell, A-, Evans, DDGR. (2006). BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer, 42( 8), 1143-50. eScholarID:1d31075
• Maurice A, Evans DDGR, Shenton A, Boggis CR M, Wilson M, Duffy S, Howell A-. (2006). The Screening of Women Aged Less Than 50 Years At Increased Risk of Breast Cancer By Virtue of Their Family History. Journal of Clinical Oncology, 42(10), 1385-90. eScholarID:1d27938
• Maurice A, Howell A-, Evans DDGR, O'Neil A, Scobie S. (2006). Predicting compliance in a breast cancer prevention trial. Breast J, 12( 5), 446-50. eScholarID:1d30903
• Maurice, A, Evans, DDGR, Shenton, A, Ashcroft, L, Baildam, A, Barr, L, Byrne, G, Bundred, N, Boggis, C, Wilson, M, Duffy, S, Howell, A-. (2006). Screening younger women with a family history of breast cancer--does early detection improve outcome? Eur J Cancer, 42( 10), 1385-90. eScholarID:1d31073
• Renehan A, Harvie M, Howell A-. (2006). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer, 13( 2), 273-8. eScholarID:1d31034
• Shanley, S, McReynolds, K, Ardern-Jones, A, Ahern, R, Fernando, I, Yarnold, J, Evans, DDGR, Eccles, D, Hodgson, S, Ashley, S, Ashcroft, L, Tutt, A, Bancroft, E, Short, S, Gui, G, Barr, L, Baildam, AD, Howell, A-, Royle, G, Pierce, L, Esaton, D, Eeles, R. (2006). Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. Clinical Cancer Research, 12(23), 7025-7032. eScholarID:1d27954
• Shanley, S, McReynolds, K, Ardern-Jones, A, Ahern, R, Fernando, I, Yarnold, J, Evans, DDGR, Eccles, D, Hodgson, S, Ashley, S, Ashcroft, L, Tutt, A, Bancroft, E, Short, S, Smith, I, Gui, G, NULL, Barr, L, Baildam, A, Howell, A-, Royle, G, Pierce, L, Easton, D, Eeles, R. (2006). Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res, 12( 23), 7033-8. eScholarID:1d31575
• Sims AH, Ong KR, Clarke RB, Clarke RB, Howell A-. (2006). High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res, 8( 5), eScholarID:1d30944
• The Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar, A, Howell, A-, Cuzick, J, Wale, C, Distler, W, Hoctin-Boes, G, Houghton, J, Locker, G, Nabholtz, J. (2006). Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol, 7( 8), 633-43. eScholarID:1d14838 | DOI:10.1016/S1470-2045(06)70767-7
• Wilson C, Sims AH, Howell A-, Miller C, Clarke RB. (2006). Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer, 13( 2), 617-28. eScholarID:1d29980

2005

• Clarke RB, Spence K, Anderson E, Howell A-, Okano H, Potten C. (2005). A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol, 277( 2), 443-56. eScholarID:1d9267 | DOI:10.1016/j.ydbio.2004.07.044
• Harvie M, Howell A-, Vierkant R, Kumar N, Cerhan J, Kelemen L, Folsom A, Sellers T. (2005). Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev, 14( 3), 656-61. eScholarID:1d11875 | DOI:10.1158/1055-9965.EPI-04-0001
• Howell A-, Buzdar A. (2005). Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol, 93( 2-5), 237-47. eScholarID:1d29771
• Howell A-, Pippen J, Elledge R, Mauriac L, Vergote I, Jones S, Come S, Osborne C, Robertson J. (2005). Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer, 104( 2), 236-9. eScholarID:1d11874 | DOI:10.1002/cncr.21163
• Howell A-. (2005). Adjuvant aromatase inhibitors for breast cancer. Lancet, 366( 9484), 431-3. eScholarID:1d29665
• Howell, A-, Cuzick, J, Baum, M, Buzdar, A, Dowsett, M, Forbes, J, Hoctin-Boes, G, Houghton, J, Locker, G, Tobias, J, ATAC Trialists' Group. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365( 9453), 60-2. eScholarID:1d9387 | DOI:10.1016/S0140-6736(04)17666-6
• Martin, M, Pienkowski, T, Mackey, J, Pawlicki, M, Guastalla, J, Weaver, C, Tomiak, E, Al-Tweigeri, T, Chap, L, Juhos, E, Guevin, R, Howell, A-, Fornander, T, Hainsworth, J, Coleman, R, Vinholes, J, Modiano, M, Pinter, T, Tang, S, Colwell, B, Prady, C, Provencher, L, Walde, D, Rodriguez-Lescure, A, Hugh, J, Loret, C, Rupin, M, Blitz, S, Jacobs, P, Murawsky, M, Riva, A, Vogel, C, NULL. (2005). Adjuvant docetaxel for node-positive breast cancer. N Engl J Med, 352( 22), 2302-13. eScholarID:1d29770

2001

• Lonning PE, Taylor PD, Anker P, Iddon J, Wie L, Jorgensen L-M, Mella O, Howell A-. (2001). High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Br Ca Res Treatment, 67, 111-116. eScholarID:1d2678

2000

• Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A-, Bundred NJ. (2000). Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis. J Natl Cancer Inst, 92, eScholarID:1d2662